## Dung Van Nguyen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2103270/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The role of ZAP and OAS3/RNAseL pathways in the attenuation of an RNA virus with elevated frequencies of CpG and UpA dinucleotides. Nucleic Acids Research, 2019, 47, 8061-8083.	6.5	75
2	Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors. Hepatology, 2019, 69, 1861-1872.	3.6	68
3	Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike–ACE2 Interaction. ACS Central Science, 2022, 8, 527-545.	5.3	62
4	Detection and Characterization of Homologues of Human Hepatitis Viruses and Pegiviruses in Rodents and Bats in Vietnam. Viruses, 2018, 10, 102.	1.5	37
5	Comparability of six different immunoassays measuring SARSâ€CoV â€2 antibodies with neutralizing antibody levels in convalescent plasma: From utility to prediction. Transfusion, 2021, 61, 2837-2843.	0.8	29
6	Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia. Journal of Hepatology, 2020, 73, 794-799.	1.8	27
7	Virological Characterization of Critically III Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection. Journal of Infectious Diseases, 2021, 224, 595-605.	1.9	20
8	Association of Zinc Finger Antiviral Protein Binding to Viral Genomic RNA with Attenuation of Replication of Echovirus 7. MSphere, 2021, 6, .	1.3	13
9	Convalescent plasma donors show enhanced crossâ€reactive neutralizing antibody response to antigenic variants of SARS oVâ€2 following immunization. Transfusion, 2022, 62, 1347-1354.	0.8	9
10	A Novel Immunofluorescence Assay for the Rapid Serological Detection of SARS-CoV-2 Infection. Viruses, 2021, 13, 747.	1.5	8
11	Recombination Analysis of Non-Poliovirus Members of the Enterovirus C Species: Restriction of Recombination Events to Members of the Same 3DPol Cluster. Viruses, 2020, 12, 706.	1.5	7
12	Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. Wellcome Open Research, 2021, 6, 93.	0.9	7
13	Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Strain Variation on Virus Neutralization Titers: Therapeutic Use of Convalescent Plasma. Journal of Infectious Diseases, 2022, 225, 971-976.	1.9	5
14	Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR. Journal of Clinical Microbiology, 2022, 60, e0228321.	1.8	5
15	Use of a small DNA virus model to investigate mechanisms of CpG dinucleotide-induced attenuation of virus replication. Journal of General Virology, 2020, 101, 1202-1218.	1.3	4
16	Detection frequencies and viral load distribution of parvovirus <scp>B19 DNA</scp> in blood and plasma donations in <scp>E</scp> ngland. Transfusion Medicine, 2022, 32, 402-409.	0.5	4
17	A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. Communications Medicine, 2022, 2, .	1.9	3
18	No Exchange of Picornaviruses in Vietnam between Humans and Animals in a High-Risk Cohort with Close Contact despite High Prevalence and Diversity. Viruses, 2021, 13, 1709.	1.5	2

#	Article	IF	CITATIONS
19	Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. Wellcome Open Research, 2021, 6, 93.	0.9	1
20	Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT. Efficacy and Mechanism Evaluation, 2021, 8, 1-90.	0.9	0